Adipose tissue is a secretory organ producing a variety of bioactive substances, such as
adiponectin.
Adiponectin has antiatherogenic properties while
plasminogen activator inhibitor type 1 (PAI-1) is closely involved in the development of
atherosclerosis. The relationship between
adiponectin and
PAI-1 in patients with
coronary artery disease (CAD) has not been clarified. This study examined plasma levels of
adiponectin and
PAI-1 in 64 patients with stable exertional angina (SEA) and 65 patients with the
chest pain syndrome (CPS). Plasma log-
adiponectin levels were significantly lower in patients with SEA (0.62+/-0.08 micro g/dL) compared to those with CPS (0.86+/-0.05 micro g/dL) (p<0.0001). The plasma levels of log-PAI-1 were significantly higher in patients with SEA (1.23+/-0.18 ng/mL) compared to those with CPS (1.15+/-0.22 ng/mL) (p<0.05). Plasma log-
adiponectin levels correlated negatively with
diabetes mellitus (DM), body mass index (BMI), log-PAI-1 (r=-0.284, p<0.001),
triglyceride (TG), and remnant-like particles
cholesterol (RLP-C), and positively with
high-density lipoprotein cholesterol (HDL-C) levels. Plasma levels of log-PAI-1 correlated positively with DM, BMI,TG and RLP-C levels, and negatively with HDL-C levels. Multiple logistic regression analysis identified sex,
angina pectoris, and
PAI-1 as independent determinants of hyperadiponectinemia (p<0.05).
Adiponectin is inversely related to
PAI-1. DM, BMI,TG, HDL-C, and RLP-C are common mediators between
adiponectin and
PAI-1, and treatment for common mediators may prevent the development of CAD by reducing
PAI-1 and increasing
adiponectin levels.